Immune checkpoint inhibitors
Immunology-based therapy is rapidly developing into an effective treatment option for a surprising range of cancers. We have learned over the last decade that powerful immunologic effector cells may be blocked by inhibitory regulatory pathways controlled by specific molecules often called "immune checkpoints." The development of a new therapeutic class of drugs that inhibit these inhibitory pathways has recently emerged as a potent strategy in oncology. Three sets of agents have emerged in clinical trials exploiting this strategy. These agents are antibody-based therapies targeting cytotoxic T-lymphocyte antigen 4 (CTLA4), programmed cell death 1 (PD-1), and programmed cell death ligand 1 (PD-L1). These inhibitors of immune inhibition have demonstrated extensive activity as single agents and in combinations. Clinical responses have been seen in melanoma, renal cell carcinoma, small cell lung cancer, and several other tumor types.
- Drugs
- Recognision of immune cells
- Attacking mechanisms
- Adverse effects of these drugs
- Considerations in Using/Prescribing
- PD-1 or PD-L1 Targetors/Targets
- Targetting CTLA-4
Related Conference of Immune checkpoint inhibitors
5th International conference on Vaccines, Vaccination and Immunization
Immune checkpoint inhibitors Conference Speakers
Recommended Sessions
- Antibody Therapy of Cancer
- Brain Tumors
- Cancer & HIV
- Cancer biomarkers
- Cancer clinical trials
- Cancer Genomics and Metabolomics
- Cancer Immunology & Immunotherapy
- Cancer micro and immuno environment
- Cancer Pharmacology
- Cancer Prognosis & Diagnosis
- Cancer Research & Cancer vaccines
- Combining Cancer Immunotherapies
- Immune checkpoint inhibitors
- Immuno-Oncology studies
- Novel Approaches in Cancer & Tumor
- Radiology and Imaging in Cancer
- Stem Cell Therapy
- Tumor biology
- Tumor Immunology
- Tumor immunotherapy research
- Tumor markers and drug targeting
- Tumors
- Types of cancer
Related Journals
Are you interested in
- Cancer Immunology and Immunotherapy - IMMUNOLOGY 2024 (Spain)
- Cell & Plant Biology - IMMUNOLOGY 2024 (Spain)
- Cell Biology - IMMUNOLOGY 2024 (Spain)
- CELL, ANIMAL & PLANT BIOLOGY - IMMUNOLOGY 2024 (Spain)
- Clinical Immunology & Current & Future Research - IMMUNOLOGY 2024 (Spain)
- Immune System - IMMUNOLOGY 2024 (Spain)
- Immuno informatics & Systems immunology - IMMUNOLOGY 2024 (Spain)
- Immuno-Genetics - IMMUNOLOGY 2024 (Spain)
- Immunogenetics - IMMUNOLOGY 2024 (Spain)
- Immunohistochemistry - IMMUNOLOGY 2024 (Spain)
- Immunology - IMMUNOLOGY 2024 (Spain)
- Immunotherapy - IMMUNOLOGY 2024 (Spain)
- Nutritional Immunology - IMMUNOLOGY 2024 (Spain)
- OncoImmunology - IMMUNOLOGY 2024 (Spain)
- Pediatric and Neonatal Immunology - IMMUNOLOGY 2024 (Spain)
- Reproductive Immunology - IMMUNOLOGY 2024 (Spain)
- Transplantation and Computational Immunology - IMMUNOLOGY 2024 (Spain)
- Vaccines & Immunization - IMMUNOLOGY 2024 (Spain)
- Virology and infectious diseases - IMMUNOLOGY 2024 (Spain)